124 related articles for article (PubMed ID: 7648837)
1. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.
Johnson CC; Slavoski L; Schwartz M; May P; Pitsakis PG; Shur AL; Levison ME
Diagn Microbiol Infect Dis; 1995 Mar; 21(3):169-73. PubMed ID: 7648837
[TBL] [Abstract][Full Text] [Related]
2. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Williams JD; Maskell JP; Whiley AC; Sefton AM
J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
[TBL] [Abstract][Full Text] [Related]
4. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Steckelberg JM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):177-9. PubMed ID: 11109018
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, Staphylococcus aureus and enterococcus spp.
Johnson AP; Warner M; Speller DC
J Antimicrob Chemother; 1997 Oct; 40(4):604-5. PubMed ID: 9372437
[No Abstract] [Full Text] [Related]
9. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
13. Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis.
Tarasi A; Dever LL; Tomasz A
J Antimicrob Chemother; 1997 May; 39 Suppl A():121-7. PubMed ID: 9511076
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
Bonilla HF; Perri MB; Kauffman CA; Zervos MJ
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):127-31. PubMed ID: 8902408
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.
Reinert RR; Kresken M; Mechery V; Lemperle M; Lütticken R
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):662-5. PubMed ID: 9832271
[TBL] [Abstract][Full Text] [Related]
16. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
Eliopoulos GM; Wennersten CB
Antimicrob Agents Chemother; 2002 May; 46(5):1319-24. PubMed ID: 11959562
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
19. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
20. Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against streptococcus pneumoniae and enterococci isolates from the western hemisphere: example of international surveillance (SENTRY antimicrobial surveillance program )in the development of new drugs.
Lewis MT; Jones RN
Braz J Infect Dis; 2000 Feb; 4(1):15-21. PubMed ID: 10788841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
